臨床泌尿器科78巻8号

2024年07月発行

特集 前立腺肥大症の診療トランスフォーメーション―低侵襲的外科治療の台頭 〈生活指導・薬物療法〉

OAB治療薬が必要な前立腺肥大症とは？

著者： 橘田岳也¹ 和田直樹¹ 柿崎秀宏¹

所属機関： ¹旭川医科大学 腎泌尿器外科学講座

ページ範囲：P.552 - P.558

▶ポイント

・前立腺肥大症に伴う過活動膀胱に対して，薬物療法は有効な選択肢である．

・薬物療法の第一選択はα遮断薬およびPDE5阻害薬である．

・併用療法は有効であるが，治療対象が高齢者であり，治療が長期にわたることも勘案すべきである．

参考文献

1） 日本排尿機能学会, 他 （編） : 過活動膀胱診療ガイドライン ［第3版］. リッチヒルメディカル, 2022

2） Yokoyama O, et al : The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 151 : 1554-1556, 1994

3） 日本泌尿器科学会 （編） : 男性下部尿路症状・前立腺肥大症診療ガイドライン. リッチヒルメディカル, 2017

4） Matsukawa Y, et al : A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia. Urology 86 : 558-564, 2015

5） Kojima Y, et al : New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia. Curr Drug Ther 5 : 262-227, 2010

6） Oelke M, et al : Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61 : 917-925, 2012

7） Matsukawa Y, et al : Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia : 1-year outcomes from a prospective urodynamic study. World J Urol 37 : 867-872, 2019

8） Kaplan SA, et al : Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder : a randomized controlled trial. JAMA 296 : 2319-2328, 2006

9） Kaplan SA, et al : Antimuscarinics for treatment of storage lower urinary tract symptoms in men : a systematic review. Int J Clin Pract 65 : 487-507, 2011

10） Yamanishi T, et al : The role of beta（3）-adrenoceptors in mediating relaxation of porcine detrusor muscle. Br J Pharmacol 135 : 129-134, 2002

-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 190 : 1320-1327, 2013

12） Shi H, et al : The efficacy and safety of Vibegron in treating overactive bladder : A systematic review and pooled analysis of randomized controlled trials. Neurourol Urodyn 39 : 1255-1263, 2020

13） Nishizawa O, et al : Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics. Low Urin Tract Symptoms 3 : 29-35, 2011

14） Yamaguchi O, et al : Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology 78 : 126-133, 2011

15） Takeda M, et al : Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH : the ADDITION study. Urology 82 : 887-893, 2013

16） Kakizaki H, et al : Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms : A Randomized, Placebo-controlled Study （MATCH）. Eur Urol Focus 6 : 729-737, 2020

17） Ishikawa K, et al : Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor : A Preliminary Study. Urology 153 : 256-263, 2021

18） Yamanishi T, et al : A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms symptoms （CONTACT Study Study）. Neurourol Urodyn 39 : 804-812, 2020

19） Ishikawa K, et al : Efficacy and Safety of Vibegron Add on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor : A Preliminary Study. Urology 153 : 256-263, 2021